Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Advertisement

Experimental & Molecular Medicine
  • View all journals
  • Search
  • My Account Login
  • Content Explore content
  • About the journal
  • Publish with us
  • Sign up for alerts
  • RSS feed
  1. nature
  2. experimental & molecular medicine
  3. articles
  4. article
Purification and characterization of human 92-kDa type IV collagenase (gelatinase B)
Download PDF
Download PDF
  • Article
  • Open access
  • Published: 01 December 1996

Purification and characterization of human 92-kDa type IV collagenase (gelatinase B)

  • Dae-Heui Lee1 &
  • Kooil Kang 

Experimental & Molecular Medicine volume 28, pages 161–165 (1996)Cite this article

  • 965 Accesses

  • 3 Citations

  • Metrics details

Abstract

Human 92-kDa type IV collagenase (gelatinase B), a family of matrix metalloproteinases (MMP), play important roles in the degradation of the basement membrane and the migration of leukocytes and metastatic tumor cells during inflammation and invasion. To investigate the biochemical and enzymatic characteristics of human neutrophil type IV collagenase, the enzyme was extracted from human leukocytes and purified by a combination of Ultrogel AcA 54 and Bio-Rex 70 chromatographies. The purified enzyme showed a single band of molecular weight of 92 kDa on SDS-PAGE. Human neutrophil type IV collagenase degraded gelatin by cleaving the specific sites, but did not affect intact type I collagen. Human 92-kDa type IV collagenase activity was inhibited by EGTA, EDTA and tetracycline. Tetracycline showed the strongest inhibitory effect on the gelatinolytic activity of the 92-kDa type IV collagenase. These inhibitory effects may be due to the chelation effect of these agents since 92-kDa type IV collagenase is a metalloenzyme.

Similar content being viewed by others

An in vitro investigation to understand the synergistic role of MMPs-1 and 9 on articular cartilage biomechanical properties

Article Open access 13 July 2021

A bioinformatics-driven approach to identify biomarkers and elucidate the pathogenesis of type 2 diabetes concurrent with pulmonary tuberculosis

Article Open access 15 May 2025

Endothelial inflammation and neutrophil transmigration are modulated by extracellular matrix composition in an inflammation-on-a-chip model

Article Open access 27 April 2022

Article PDF

Author information

Authors and Affiliations

  1. Department of Pharmacology, Kosin Medical College, Pusan, 602-702, Korea

    Dae-Heui Lee

Authors
  1. Dae-Heui Lee
    View author publications

    Search author on:PubMed Google Scholar

  2. Kooil Kang
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and permissions

About this article

Cite this article

Lee, DH., Kang, K. Purification and characterization of human 92-kDa type IV collagenase (gelatinase B). Exp Mol Med 28, 161–165 (1996). https://doi.org/10.1038/emm.1996.25

Download citation

  • Published: 01 December 1996

  • Issue date: 01 December 1996

  • DOI: https://doi.org/10.1038/emm.1996.25

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

Keywords

  • human neutrophil
  • type IV collagenase
  • tetracycline
Download PDF

Advertisement

Explore content

  • Research articles
  • Reviews & Analysis
  • News & Comment
  • Current issue
  • Collections
  • Sign up for alerts
  • RSS feed

About the journal

  • Special Feature
  • Journal Information
  • About the Editors
  • About the Partner
  • Contact
  • For Advertisers
  • Press Releases
  • Open Access Fees and Funding

Publish with us

  • For Authors & Referees
  • Language editing services
  • Submit manuscript

Search

Advanced search

Quick links

  • Explore articles by subject
  • Find a job
  • Guide to authors
  • Editorial policies

Experimental & Molecular Medicine (Exp Mol Med)

ISSN 2092-6413 (online)

ISSN 1226-3613 (print)

nature.com sitemap

About Nature Portfolio

  • About us
  • Press releases
  • Press office
  • Contact us

Discover content

  • Journals A-Z
  • Articles by subject
  • protocols.io
  • Nature Index

Publishing policies

  • Nature portfolio policies
  • Open access

Author & Researcher services

  • Reprints & permissions
  • Research data
  • Language editing
  • Scientific editing
  • Nature Masterclasses
  • Research Solutions

Libraries & institutions

  • Librarian service & tools
  • Librarian portal
  • Open research
  • Recommend to library

Advertising & partnerships

  • Advertising
  • Partnerships & Services
  • Media kits
  • Branded content

Professional development

  • Nature Awards
  • Nature Careers
  • Nature Conferences

Regional websites

  • Nature Africa
  • Nature China
  • Nature India
  • Nature Japan
  • Nature Middle East
  • Privacy Policy
  • Use of cookies
  • Legal notice
  • Accessibility statement
  • Terms & Conditions
  • Your US state privacy rights
Springer Nature

© 2025 Springer Nature Limited